Robert Benedikt Höh, Rocco Flammia, Lukas Hohenhorst, Gabriele Sorce, Francesco Chierigo, Zhe Tian, Fred Saad, Michele Gallucci, Alberto Briganti, Carlo Terrone, Shahrokh F. Shariat, Markus Graefen, Derya Tilki, Luis A. Kluth, Philipp Mandel, Felix Chun, Pierre I. Karakiewicz
- Background: Up- and/or downgrading rates in single intermediate-risk positive biopsy core are unknown.
Methods: We identified single intermediate-risk (Gleason grade group (GGG) 2/GGG3) positive biopsy core prostate cancer patients (≤ cT2c and PSA ≤ 20 ng/mL) within the Surveillance, Epidemiology, and End Results (SEER) database (2010–2015). Subsequently, separate uni- and multivariable logistic regression models tested for independent predictors of up- and downgrading.
Results: Of 1,328 assessable patients with single core positive intermediate-risk prostate cancer at biopsy, 972 (73%) harbored GGG2 versus 356 (27%) harbored GGG3. Median PSA (5.5 vs 5.7; p = 0.3), median age (62 vs 63 years; p = 0.07) and cT1-stage (77 vs 75%; p = 0.3) did not differ between GGG2 and GGG3 patients. Of individuals with single GGG2 positive biopsy core, 191 (20%) showed downgrading to GGG1 versus 35 (4%) upgrading to GGG4 or GGG5 at RP. Of individuals with single GGG3 positive biopsy core, 36 (10%) showed downgrading to GGG1 versus 42 (12%) significant upgrading to GGG4 or GGG5 at RP. In multivariable logistic regression models, elevated PSA (10–20 ng/mL) was an independent predictor of upgrading to GGG4/GGG5 in single GGG3 positive biopsy core patients (OR:2.89; 95%-CI: 1.31–6.11; p = 0.007).
Conclusion: In single GGG2 positive biopsy core patients, downgrading was four times more often recorded compared to upgrading. Conversely, in single GGG3 positive biopsy core patients, up- and downgrading rates were comparable and should be expected in one out of ten patients.
MetadatenVerfasserangaben: | Robert Benedikt HöhORCiDGND, Rocco FlammiaORCiD, Lukas HohenhorstORCiD, Gabriele SorceORCiD, Francesco ChierigoORCiD, Zhe Tian, Fred SaadORCiDGND, Michele GallucciORCiD, Alberto BrigantiORCiD, Carlo TerroneORCiDGND, Shahrokh F. ShariatORCiDGND, Markus GraefenORCiDGND, Derya TilkiORCiDGND, Luis A. KluthORCiDGND, Philipp MandelORCiDGND, Felix ChunORCiDGND, Pierre I. Karakiewicz |
---|
URN: | urn:nbn:de:hebis:30:3-785492 |
---|
DOI: | https://doi.org/10.1016/j.prnil.2022.01.004 |
---|
ISSN: | 2287-8882 |
---|
Titel des übergeordneten Werkes (Englisch): | Prostate international |
---|
Verlag: | Elsevier |
---|
Verlagsort: | Amsterdam |
---|
Dokumentart: | Wissenschaftlicher Artikel |
---|
Sprache: | Englisch |
---|
Datum der Veröffentlichung (online): | 22.02.2022 |
---|
Datum der Erstveröffentlichung: | 26.01.2022 |
---|
Veröffentlichende Institution: | Universitätsbibliothek Johann Christian Senckenberg |
---|
Datum der Freischaltung: | 07.02.2024 |
---|
Freies Schlagwort / Tag: | Downgrading; Intermediate-risk; Prostate cancer; Single positive core biopsy; Upgrading |
---|
Jahrgang: | 10 |
---|
Ausgabe / Heft: | 1 |
---|
Seitenzahl: | 7 |
---|
Erste Seite: | 21 |
---|
Letzte Seite: | 27 |
---|
HeBIS-PPN: | 520983122 |
---|
Institute: | Medizin |
---|
DDC-Klassifikation: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
---|
Sammlungen: | Universitätspublikationen |
---|
Lizenz (Deutsch): | Creative Commons - CC BY-NC-ND - Namensnennung - Nicht kommerziell - Keine Bearbeitungen 4.0 International |
---|